/SCPH
SCPH Stock - scPharmaceuticals Inc.
Healthcare|BiotechnologyNASDAQ
$5.67+0.00%
+$0.00 (+0.00%) • Oct 7
71
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.92
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).50
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+0.2%upside
Target: $5.68
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SCPH
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.61 – $5.73
TARGET (TP)$5.68
STOP LOSS$5.22
RISK/REWARD1:0.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.30
52W High$6.28
52W Low$1.94
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $36.33M | $13.59M | N/A | N/A | N/A |
| Gross Profit | $24.97M | $9.78M | $-468,000 | $-438,000 | $-399,000 |
| Gross Margin | 68.7% | 72.0% | N/A | N/A | N/A |
| Operating Income | $-64,776,000 | $-55,396,000 | $-36,157,000 | $-25,823,000 | $-29,933,000 |
| Net Income | $-85,148,000 | $-54,810,000 | $-36,838,000 | $-28,034,000 | $-32,209,000 |
| Net Margin | -234.4% | -403.2% | N/A | N/A | N/A |
| EPS | $-1.91 | $-1.42 | $-1.30 | $-1.02 | $-1.31 |
Company Overview
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish0 Neutral/Bearish
Price Targets
$16
Average Target
↑ 182.2% Upside
Now
$10
Low
$16
Average
$25
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 7th 2023 | Craig Hallum | Initiation | Buy | $20 |
| December 1st 2022 | Cowen | Initiation | Outperform | $25 |
| October 21st 2022 | Jefferies | Resumed | Buy | $14 |
| October 11th 2022 | SVB Leerink | Upgrade | Outperform | $11 |
| August 2nd 2022 | Maxim Group | Initiation | Buy | $10 |
Earnings History & Surprises
SCPHBeat Rate
65%
Last 20 quarters
Avg Surprise
+4.0%
EPS vs Estimate
Beats / Misses
13/6
1 met exactly
Latest EPS
$-0.37
Q4 2025
EPS Surprise History
Q1 24
+16.7%
$-0.35vs$-0.42
Q2 24
+20.0%
$-0.36vs$-0.45
Q3 24
0.0%
$-0.44vs$-0.44
Q4 24
-23.3%
$-0.37vs$-0.30
Q1 25
+12.5%
$-0.35vs$-0.40
Q2 25
-25.9%
$-0.34vs$-0.27
Q3 25
-13.3%
$-0.34vs$-0.30
Q4 25
-48.0%
$-0.37vs$-0.25
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 12, 2025 | $-0.25 | $-0.37 | -48.0% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.30 | $-0.34 | -13.3% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.27 | $-0.34 | -25.9% | ✗ MISS |
Q1 2025 | Mar 19, 2025 | $-0.40 | $-0.35 | +12.5% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.30 | $-0.37 | -23.3% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.44 | $-0.44 | 0.0% | = MET |
Q2 2024 | May 14, 2024 | $-0.45 | $-0.36 | +20.0% | ✓ BEAT |
Q1 2024 | Mar 13, 2024 | $-0.42 | $-0.35 | +16.7% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-0.36 | $-0.41 | -13.9% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.37 | $-0.36 | +2.7% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $-0.36 | $-0.30 | +16.7% | ✓ BEAT |
Q1 2023 | Mar 22, 2023 | $-0.42 | $-0.30 | +28.6% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-0.41 | $-0.37 | +9.8% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.32 | $-0.35 | -9.4% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-0.31 | $-0.28 | +9.7% | ✓ BEAT |
Q1 2022 | Mar 22, 2022 | $-0.34 | $-0.27 | +20.6% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $-0.32 | $-0.24 | +25.0% | ✓ BEAT |
Q3 2021 | Aug 11, 2021 | $-0.30 | $-0.26 | +13.3% | ✓ BEAT |
Q2 2021 | May 12, 2021 | $-0.31 | $-0.26 | +16.1% | ✓ BEAT |
Q1 2021 | Mar 23, 2021 | $-0.36 | $-0.28 | +22.2% | ✓ BEAT |
Latest News
Craig-Hallum Downgrades scPharmaceuticals to Hold, Announces $6 Price Target
📉 NegativeBenzinga•Aug 26, 2025, 06:01 PM
Maxim Group Downgrades scPharmaceuticals to Hold
📉 NegativeBenzinga•Aug 25, 2025, 06:57 PM
Trading Halt: Halt status updated at 7:55:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Aug 25, 2025, 11:55 AM
Trading Halt: Halted at 7:25:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Aug 25, 2025, 11:25 AM
Frequently Asked Questions about SCPH
What is SCPH's current stock price?
scPharmaceuticals Inc. (SCPH) is currently trading at $5.67 per share. The stock has moved +0.00% today.
What is the analyst price target for SCPH?
The average analyst price target for SCPH is $5.68, based on 1 analyst.
What sector is scPharmaceuticals Inc. in?
scPharmaceuticals Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SCPH's market cap?
scPharmaceuticals Inc. has a market capitalization of $0.30 billion, making it a small-cap company.
Does SCPH pay dividends?
No, scPharmaceuticals Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCKPT
Checkpoint Therapeutics, Inc.
$4.26
Mkt Cap: $0.4B
CLYM
Climb Bio, Inc.
$4.28
Mkt Cap: $0.3B
INZY
Inozyme Pharma, Inc.
$4.00
Mkt Cap: $0.3B
LAB
Standard BioTools Inc.
$1.63
Mkt Cap: $0.6B
ORTX
Orchard Therapeutics plc
$16.70
Mkt Cap: $0.4B
SLRN
Acelyrin, Inc.
$2.27
Mkt Cap: $0.2B
SPPI
Spectrum Pharmaceuticals, Inc.
$1.02
Mkt Cap: $0.2B
THRD
Third Harmonic Bio, Inc.
$5.38
Mkt Cap: $0.2B
TSVT
2seventy bio, Inc.
$5.00
Mkt Cap: $0.3B
VIGL
Vigil Neuroscience, Inc.
$8.05
Mkt Cap: $0.4B
Explore stocks similar to SCPH for comparison